HCC vs. CERE, CNX, ARCH, HNRG, CEIX, METC, AREC, WES, TPL, and OVV
Should you be buying Warrior Met Coal stock or one of its competitors? The main competitors of Warrior Met Coal include Cerevel Therapeutics (CERE), CNX Resources (CNX), Arch Resources (ARCH), Hallador Energy (HNRG), CONSOL Energy (CEIX), Ramaco Resources (METC), American Resources (AREC), Western Midstream Partners (WES), Texas Pacific Land (TPL), and Ovintiv (OVV).
Cerevel Therapeutics (NASDAQ:CERE) and Warrior Met Coal (NYSE:HCC) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, community ranking, dividends and earnings.
Warrior Met Coal has a net margin of 25.94% compared to Warrior Met Coal's net margin of 0.00%. Cerevel Therapeutics' return on equity of 24.71% beat Warrior Met Coal's return on equity.
Cerevel Therapeutics has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500. Comparatively, Warrior Met Coal has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500.
87.7% of Cerevel Therapeutics shares are owned by institutional investors. Comparatively, 92.3% of Warrior Met Coal shares are owned by institutional investors. 5.1% of Cerevel Therapeutics shares are owned by company insiders. Comparatively, 1.0% of Warrior Met Coal shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, Cerevel Therapeutics had 2 more articles in the media than Warrior Met Coal. MarketBeat recorded 10 mentions for Cerevel Therapeutics and 8 mentions for Warrior Met Coal. Cerevel Therapeutics' average media sentiment score of 1.04 beat Warrior Met Coal's score of 0.54 indicating that Warrior Met Coal is being referred to more favorably in the news media.
Warrior Met Coal has higher revenue and earnings than Cerevel Therapeutics.
Cerevel Therapeutics currently has a consensus price target of $42.67, suggesting a potential upside of 6.61%. Warrior Met Coal has a consensus price target of $72.80, suggesting a potential upside of 7.71%. Given Cerevel Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Warrior Met Coal is more favorable than Cerevel Therapeutics.
Warrior Met Coal received 194 more outperform votes than Cerevel Therapeutics when rated by MarketBeat users. However, 66.52% of users gave Cerevel Therapeutics an outperform vote while only 62.66% of users gave Warrior Met Coal an outperform vote.
Summary
Warrior Met Coal beats Cerevel Therapeutics on 11 of the 15 factors compared between the two stocks.
Get Warrior Met Coal News Delivered to You Automatically
Sign up to receive the latest news and ratings for HCC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Warrior Met Coal Competitors List
Related Companies and Tools
